LIVMARLI DIN 02565250
Health Canada record
| Active ingredient(s) | MARALIXIBAT (MARALIXIBAT CHLORIDE) 20 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A05AX04 MARALIXIMAB CHLORIDE |
| Original market date | 13-Apr-2026 |
| Current status date | 13-Apr-2026 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MARALIXIBAT (MARALIXIBAT CHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02539888 | LIVMARLI | MIRUM PHARMACEUTICALS, INC. | Solution | MARALIXIBAT (MARALIXIBAT CHLORIDE) 9.5 MG | Marketed |
| 02565234 | LIVMARLI | MIRUM PHARMACEUTICALS, INC. | Tablet | MARALIXIBAT (MARALIXIBAT CHLORIDE) 10 MG | Marketed |
| 02565242 | LIVMARLI | MIRUM PHARMACEUTICALS, INC. | Tablet | MARALIXIBAT (MARALIXIBAT CHLORIDE) 15 MG | Marketed |
| 02565269 | LIVMARLI | MIRUM PHARMACEUTICALS, INC. | Tablet | MARALIXIBAT (MARALIXIBAT CHLORIDE) 30 MG | Marketed |
| 02565277 | LIVMARLI | MIRUM PHARMACEUTICALS, INC. | Solution | MARALIXIBAT (MARALIXIBAT CHLORIDE) 19 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36814 | 2026-01-30 | Supplement to a New Drug Submission (SNDS) | Addition of new indication: treatment of cholestatic pruritus in patients aged 12 months or older with progressive familial intrahepatic cholestasis (PFIC). Limitations of use: Livmarli may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-function or complete absence of the bile salt export pump protein. Addition of new dosage form: Tablets Addition of new strength: Oral solution, 19 mg/mL |